



ASX ANNOUNCEMENT

Core Camera Reader Patent Granted in Europe and Japan

MELBOURNE, Australia (16 Aug 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce that a core patent covering the camera technology used in its reader platform has been granted for Europe and Japan.

The patent, entitled “*Device for reading an IVD assay*”, covers the use of Lumos’ proprietary camera technology which is incorporated in many of its readers. These readers have become a critical component of new point-of-care tests as they automate the reading and quantification of results and allow those results to be seamlessly integrated into electronic medical record systems. As these rapid diagnostic test readers promote more consistent, accurate test performance, interpretation and reporting, they are becoming a key requirement for the successful adoption of point-of-care tests by healthcare professionals in a variety of medical settings.

This patent covers the use of Lumos’ reader technology in the European and Japanese markets until 2036 and has already been granted in the United States and Australia.

“We are delighted to have this patent, which covers a core component of our reader technology, awarded for the European and Japanese markets” said Doug Ward, CEO and Managing Director of Lumos. “Access to our proprietary reader technology is highly valued by our clients and partners, and has been a significant consideration for many of the development contracts that we have recently secured. Having this technology covered by granted patents in the US, Australian, European and Japanese markets is important for Lumos and its clients from both competitive and commercial perspectives.”

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598